Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -18.55%-131.76M | -135.20%-56.12M | -18.46%-27.5M | 12.61%-27.28M | 36.50%-20.86M | 39.94%-111.14M | 17.17%-23.86M | 48.32%-23.22M | 45.44%-31.21M | 39.30%-32.85M |
Net income from continuing operations | -48.30%-182.82M | -118.32%-58.68M | -110.74%-51.91M | 4.77%-32.68M | -5.60%-39.55M | 42.40%-123.28M | 34.72%-26.88M | 43.95%-24.63M | 43.00%-34.31M | 45.49%-37.46M |
Depreciation and amortization | -17.13%358K | -57.66%47K | -15.60%92K | 0.94%107K | 5.66%112K | 3.10%432K | 5.71%111K | 6.86%109K | -10.92%106K | 13.98%106K |
Other non cash items | 310.16%3.43M | 11.47%243K | 11.32%236K | 11.65%230K | 1,255.22%2.72M | 11.30%837K | 11.22%218K | 11.58%212K | 10.75%206K | 11.67%201K |
Change In working capital | 177.83%10.92M | -61.88%-4.92M | 392.59%13.66M | 123.91%715K | 144.03%1.47M | -687.87%-14.03M | -155.20%-3.04M | 43.12%-4.67M | 41.97%-2.99M | -154.92%-3.34M |
-Change in prepaid assets | -221.46%-8.23M | -557.37%-8.79M | -44.60%1.82M | -114.72%-449K | -145.62%-808K | 1,138.03%6.77M | 24.85%-1.34M | 104.93%3.29M | 71.12%3.05M | 266.92%1.77M |
-Change in payables and accrued expense | 231.53%22.82M | 707.89%5.62M | 271.71%12.42M | 135.94%1.8M | 171.25%2.98M | -163.99%-17.35M | -136.76%-925K | 24.53%-7.23M | 24.20%-5.01M | -158.89%-4.18M |
-Change in other current liabilities | -12.04%-1.13M | -11.49%-291K | -12.60%-286K | -11.20%-278K | -12.92%-271K | -23.92%-1.01M | -12.02%-261K | -12.39%-254K | 23.31%-250K | -823.08%-240K |
-Change in other working capital | -4.25%-2.55M | -183.69%-1.46M | 36.32%-298K | 54.03%-359K | 36.60%-433K | -148.40%-2.45M | -110.30%-515K | ---468K | ---781K | -1,319.64%-683K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -18.55%-131.76M | -135.20%-56.12M | -18.46%-27.5M | 12.61%-27.28M | 36.50%-20.86M | 39.94%-111.14M | 17.17%-23.86M | 48.32%-23.22M | 45.44%-31.21M | 39.30%-32.85M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -737.98%-248.49M | -21,736.00%-10.92M | 49.57M | -4,018.44%-195.92M | -368.29%-91.22M | -59.80%38.95M | -100.22%-50K | 0 | -85.67%5M | 497.66%34M |
Net PPE purchase and sale | --0 | ---- | ---- | ---- | ---- | 88.74%-50K | ---- | ---- | ---- | ---- |
Net investment purchase and sale | -737.16%-248.49M | ---10.92M | --49.57M | -4,018.44%-195.92M | -368.29%-91.22M | -59.93%39M | --0 | --0 | -85.71%5M | 511.57%34M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -737.98%-248.49M | -21,736.00%-10.92M | --49.57M | -4,018.44%-195.92M | -368.29%-91.22M | -59.80%38.95M | -100.22%-50K | --0 | -85.67%5M | 497.66%34M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 459.83%514.32M | 2,657.32%113.77M | 1.44M | 210.53%216.36M | 911.38%182.76M | 777.89%91.87M | -23.41%4.13M | 0 | 13,724.40%69.68M | 1,394.62%18.07M |
Net common stock issuance | 459.00%512M | 2,681.37%111.95M | --1.24M | 211.01%216.06M | 909.90%182.75M | 857.98%91.59M | -23.05%4.03M | --0 | --69.47M | 1,222.81%18.1M |
Proceeds from stock option exercised by employees | 532.93%2.63M | 1,762.26%1.97M | 20,000.00%201K | 51.44%315K | 41.58%143K | -70.83%416K | -34.97%106K | -99.76%1K | -60.00%208K | -69.67%101K |
Net other financing activities | -124.82%-308K | -3,040.00%-157K | 0.00%-1K | -225.00%-13K | -7.87%-137K | 73.75%-137K | 28.57%-5K | 85.71%-1K | 75.00%-4K | 74.19%-127K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 459.83%514.32M | 2,657.32%113.77M | --1.44M | 210.53%216.36M | 911.38%182.76M | 777.89%91.87M | -23.41%4.13M | --0 | 13,724.40%69.68M | 1,394.62%18.07M |
Net cash flow | ||||||||||
Beginning cash position | 31.73%81.72M | 66.56%169.06M | 16.71%145.56M | 87.55%152.4M | 31.73%81.72M | -55.60%62.03M | 61.48%101.5M | 120.91%124.72M | 3.81%81.26M | -55.60%62.03M |
Current changes in cash | 581.09%134.07M | 336.17%46.73M | 201.24%23.5M | -115.73%-6.84M | 267.67%70.68M | 125.34%19.69M | -2,298.18%-19.79M | -462.68%-23.22M | 299.23%43.46M | 131.28%19.22M |
End cash Position | 164.07%215.79M | 164.07%215.79M | 66.56%169.06M | 16.71%145.56M | 87.55%152.4M | 31.73%81.72M | 31.73%81.72M | 61.48%101.5M | 120.91%124.72M | 3.81%81.26M |
Free cash flow | -18.50%-131.76M | -134.71%-56.12M | -18.46%-27.5M | 12.61%-27.28M | 36.50%-20.86M | 40.06%-111.19M | 16.99%-23.91M | 48.37%-23.22M | 45.54%-31.21M | 39.62%-32.85M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |